Translating Research for the Radiotheranostics of Nanotargeted 188Re-Liposome

Abstract

Nanoliposomes are one of the leading potential nano drug delivery systems capable of targeting chemotherapeutics to tumor sites because of their passive nano-targeting capability through the enhanced permeability and retention (EPR) effect for cancer patients. Recent advances in nano-delivery systems have inspired the development of a wide range of nanotargeted materials and strategies for applications in preclinical and clinical usage in the cancer field. Nanotargeted 188Re-liposome is a unique internal passive radiotheranostic agent for nuclear imaging and radiotherapeutic applications in various types of cancer. This article reviews and summarizes our multi-institute, multidiscipline, and multi-functional studied results and achievements in the research and development of nanotargeted 188Re-liposome from preclinical cells and animal models to translational clinical investigations, including radionuclide nanoliposome formulation, targeted nuclear imaging, biodistribution, pharmacokinetics, radiation dosimetry, radiation tumor killing effects in animal models, nanotargeted radionuclide and radio/chemo-combination therapeutic effects, and acute toxicity in various tumor animal models. The systemic preclinical and clinical studied results suggest 188Re-liposome is feasible and promising for in vivo passive nanotargeted radionuclide theranostics in future cancer care applications.

Development of a Supermolecular Radionuclide-Drug Conjugate System for Integrated Radiotheranostics for Non-small Cell Lung Cancer

“…Its economical and simple manufacturing technique might facilitate its clinical translation. The hydrogen bond-driving self-assembled radioactive supermolecule ( 131 I-ER-Fu NPs) showed superiority to the currently existing delivery systems, including liposome, polymer, , and inorganic nanomaterials. , First, dose-fixed Fu was added, and no covalent interaction was generated between Fu and 131 I-ER. 131 I-ER-Fu NPs was structure clear and QC stable for administration, which was consistent to 131 I-ER.…”

Radionuclide Delivery Strategies in Tumor Treatment: A Systematic Review

“…They will probably be tested for the simultaneous delivery of therapeutic radionuclides and chemotherapeutic agents with a view to their use in combined therapies; however, before that can happen, we need to solve the variability in their deposition in tumors, and their nonspecific uptake in the liver. Until now, very preliminary data are available about the labeling of liposomes with rhenium-186 [ 45 , 46 ]. However, as illustrated in Table 4 , two clinical trials are ongoing for testing this therapeutic opportunity in patients with primary or secondary brain disease.…”

Radiolabeled Liposomes for Nuclear Imaging Probes

“…Identically, the radionuclide was encapsulated in the intraliposomal space during the radiolabeling process with the help of a chelating agent. It is important to note that knowledge of the coordination chemistry of each radionuclide and relevant chelator is required to accurately propose a suitable chelating agent [88,89].…”